Pharmacovigilance data for pdVWF/FVIII concentrate in a ratio of 2.4:1

Speakers: Günter Auerswald and Will Thomas

In the final video of this collection, Günter Auerswald and Will Thomas, present the post-marketing surveillance and pharmacovigilance data for plasma-derived von Willebrand Factor and Factor VIII concentrate (pdVWF/FVIII) in a ratio of 2.4:1, which have never been reported previously. Günter Auerswald and Will Thomas are two of the authors of a recently published systematic literature review of the efficacy and safety of plasma-derived von Willebrand Factor and Factor VIII concentrate (pdVWF/FVIII) in a ratio of 2.4:1 in von Willebrand disease, and you can watch their other videos describing the efficacy and safety of plasma-derived von Willebrand Factor and Factor VIII concentrate (pdVWF/FVIII) in a ratio of 2.4:1 in long-term prophylaxis, on-demand treatment of bleeds and surgical prophylaxis for von Willebrand disease within this collection.